Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation

Jie Huang; Shi-Ling Zhang; Chao Zhang; Weiye Huang; Zhenhua Zhang; Yu-Qing Chen; Jun-Wei Su; Hong-Hong Yan; Hua-Jun Chen; Jin-Ji Yang; Junjian Wang; Yi-Long Wu

doi:10.1002/ctm2.1683

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (5) : e1683 DOI: 10.1002/ctm2.1683

LETTER TO THE JOURNAL

Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation

Author information +

History +

PDF

Cite this article

Download citation ▾

Jie Huang, Shi-Ling Zhang, Chao Zhang, Weiye Huang, Zhenhua Zhang, Yu-Qing Chen, Jun-Wei Su, Hong-Hong Yan, Hua-Jun Chen, Jin-Ji Yang, Junjian Wang, Yi-Long Wu. Genotyping of RB1 status identifies two distinct subtypes in EGFR-mutant lung cancers with SCLC transformation. Clinical and Translational Medicine, 2024, 14(5): e1683 DOI:10.1002/ctm2.1683

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.

[2]	Hwang S, Hong TH, Park S, et al. Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment. Transl Lung Cancer Res. 2021;10(11):4209-4220.

[3]	Marcoux N, Gettinger SN, O'Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37(4):278-285.

[4]	Wang W, Xu C, Chen H, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: a multicenter retrospective study. Lung Cancer. 2021;155:20-27.

[5]	Zhong J, Li X, Wang Z, et al. Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas. Journal of the National Cancer Center. 2021;1(4):153-162.

[6]	Pros E, Saigi M, Alameda D, et al. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors. Ann Oncol. 2020;31(2):274-282.

[7]	Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784-1793.

[8]	Zhang CY, Sun H, Su JW, et al. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. Lung Cancer. 2023;175:68-78.

[9]	Chakraborty S, Coleman C, Manoj P, et al. De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways. Clin Cancer Res. 2023;29(17):3526-3540.

[10]	Quintanal-Villalonga A, Taniguchi H, Zhan YA, et al. Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021;11(12):3028-3047.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.